Search results
Results from the WOW.Com Content Network
Three misconceptions are that AIDS can spread through casual contact, that sexual intercourse with a virgin will cure AIDS, [302] [303] [304] and that HIV can infect only gay men and drug users. [ 305 ] [ 306 ] In 2014, some among the British public wrongly thought one could get HIV from kissing (16%), sharing a glass (5%), spitting (16%), a ...
The management of HIV/AIDS typically involves the use of multiple antiretroviral drugs. In many parts of the world, HIV has become a chronic condition, with progression to AIDS increasingly rare. HIV latency and the resulting viral reservoir in CD4 + T cells, dendritic cells, and macrophages is the main barrier to eradication of the virus. [19 ...
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy ...
CD4 T-cell depletion and chronic inflammation are the two signature events that drive HIV pathogenesis and progression to AIDS. Infection of the cells of the CNS cause acute aseptic meningitis, subacute encephalitis, vacuolar myelopathy and peripheral neuropathy. Later it leads to even AIDS dementia complex.
Lamivudine, commonly called 3TC, is an antiretroviral medication used to prevent and treat HIV/AIDS. [1] It is also used to treat chronic hepatitis B when other options are not possible. [1] It is effective against both HIV-1 and HIV-2. [1] It is typically used in combination with other antiretrovirals such as zidovudine, dolutegravir, and ...
U.S. FDA approves Gilead's long-acting HIV drug Sunlenca December 22, 2022 at 11:26 AM FILE PHOTO: The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California
HPA-23 was developed by Rhône-Poulenc at the Pasteur Institute in the 1970s and used in France on an experimental basis to treat HIV and AIDS patients beginning in 1984. [1] [2] The inventors of the drug, as listed in its patent, were Jean-Claude Chermann, Dominique Dormont, Etienne Vilmer, Bruno Spire, Françoise Barré-Sinoussi, Luc Montagnier, and Willy Rozenbaum. [3]
The drug falls under GSK's ViiV Healthcare business, in which Pfizer and Shionogi hold small stakes. Strong sales of medicines for HIV, the virus that causes AIDS, were one of the drivers behind ...